Holen Sie sich die Stockscreener-App
2.69
3.58%
-0.10
Handel nachbörslich:
2.69
Inozyme Pharma Inc Aktie (INZY) Neueste Nachrichten
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks - MSN
Does Inozyme Pharma (NASDAQ:INZY) Have A Healthy Balance Sheet? - Simply Wall St
Inozyme Pharma stock hits 52-week low at $3.23 amid market shifts - Investing.com
Eventide Asset Management's Strategic Acquisition of Inozyme Pha - GuruFocus.com
Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewswire
Inozyme Pharma CEO to Present at Stifel and Jefferies Healthcare Conferences | INZY Stock News - StockTitan
Inozyme Pharma’s (INZY) Buy Rating Reiterated at HC Wainwright - Defense World
Inozyme Pharma (NASDAQ:INZY) Given “Outperform” Rating at Wedbush - Defense World
FY2024 EPS Estimates for Inozyme Pharma Increased by Analyst - Defense World
Inozyme Pharma FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
FY2024 EPS Estimates for Inozyme Pharma Raised by Analyst - MarketBeat
Piper Sandler raises Inozyme Pharma target to $43 from $40 - Investing.com India
Inozyme Pharma's (INZY) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewswire
Inozyme Pharma’s Q3 2024 Financial and Clinical Progress - TipRanks
Piper Sandler raises Inozyme Pharma target to $43 from $40 By Investing.com - Investing.com Canada
Inozyme Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Inozyme Pharma Reports Wider Q3 Loss, Advances Key Clinical Trials Despite $24.6M Loss | INZY Stock News - StockTitan
Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) Price Target at $16.14 - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Average Rating of “Buy” from Analysts - Defense World
Needham & Company LLC Reiterates Buy Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
Inozyme reports positive trial results for kidney disease therapy - Investing.com India
Inozyme reports positive trial results for kidney disease therapy By Investing.com - Investing.com Canada
Inozyme Pharma Bullish on Treatment for End-Stage Kidney Disease - MarketWatch
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewswire
The Manufacturers Life Insurance Company Grows Position in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
(INZY) Proactive Strategies - Stock Traders Daily
Inozyme Pharma presents kidney disease study at ASN Kidney Week By Investing.com - Investing.com Nigeria
Inozyme Pharma presents kidney disease study at ASN Kidney Week - Investing.com
Inozyme Pharma Announces Presentation of Interim Data from - GlobeNewswire
Short Interest in Inozyme Pharma, Inc. (NASDAQ:INZY) Decreases By 6.9% - MarketBeat
Dimensional Fund Advisors LP Purchases 205,417 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Millennium Management LLC Acquires 1,084,341 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) - MarketBeat
Cubist Systematic Strategies LLC Invests $84,000 in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma appoints new board member - Investing.com
Inozyme Pharma appoints new board member By Investing.com - Investing.com South Africa
Inozyme Pharma Welcomes New Director Erik Harris - TipRanks
Inozyme appoints Erik Harris to board of directors - TipRanks
Inozyme Pharma Appoints Erik Harris to its Board of Directors - citybiz
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its - The Bakersfield Californian
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors - GlobeNewswire
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of - EIN News
How the (INZY) price action is used to our Advantage - Stock Traders Daily
Inozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by American Century Companies Inc. - Defense World
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY) - MarketBeat
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):